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ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA 
Yttrium-90 radioembolization for the treatment of unresectable liver cancer: 
Results of a single center 
Rezeke edilemeyen karaciğer tümörlerinde yttrium-90 radyoembolizan tedavi: Tek merkez 
sonuçları
Özhan Özgür1, Şeyda Gündüz2, Metin Erkılıç3, Hakan Şat Bozcuk2, Hakkı Timur Sindel1
ÖZET
Amaç:  Çalışmamızda  kemoterapiden  fayda  görmeyen, 
rezeke edilemeyen karaciğer kanserlerinde yttrium-90 (Y-
90) resin mikrosfer radyoembolizasyon terapisinin etkinli-
ğinin ortaya konması amaçlanmıştır.
Yöntemler: Çalışmaya radyoembolizasyon tedavisi uy-
gulanan, rezeke edilemeyen primer veya gastrointestinal 
sistemden metastatik 55 hasta dahil edilmiştir. Üç hasta 
ön değerlendirme anjiografisi sonrasında çalışma dışı bı-
rakılmıştır. Kalan 52 hastanın 13’ü (%23.6) hepatosellü-
ler karsinoma, 39’u (%76.4) metastatik karaciğer kanseri 
hastasıdır. Elli iki hasta radyoembolizan tedavi görmüştür. 
Her  hastaya  verilen  tedavi,  Solid Tümörlerde Tedaviye 
Yanıt Kritirleri’ne (RECIST) göre değerlendirilmiş ve tüm 
sürvi  olasılığı  Kaplan-Meier  metoduna  ile  grafik  olarak 
gösterilmiştir. 
Bulgular: Y-90 tedavisi sonrası 47 hasta takip edilebil-
miştir. Hastaların %57’sinde klinik fayda yanıtı alınmış, 
%43’ünde  hastalık  progresyon  göstermiştir.  Hastaların 
medyan hepatik progresyonsuz survi süresi 3.4 ay (%95 
confidence  interval  (ci):  1.4-5.3),  tüm  sürvi  süresi  11.3 
(%95 confidence interval (ci): 8.7-14.03) olarak saptan-
mıştır.
Sonuç: Bu çalışma Y-90 resin mikrosfer radyoembolizan 
tedavinin rezeke edilemeyen karaciğer kanseri hastala-
rında etkin olduğunu ortaya koymaktadır.
Anahtar kelimeler: Yttrium-90, radyoembolizasyon, anji-
ografi, karaciğer kanseri
ABSTRACT
Objective: To determine the effects of yttrium-90 (Y-90) 
resin microsphere radioembolization therapy on patients 
with unresectable liver cancer who do not benefit from 
chemotherapy. 
Methods: Fifty-five patients underwent radioembolization 
therapy included in the study whose had unresectable 
primary  or  metastatic  liver  cancer  originating  from  the 
gastrointestinal tract. Three were excluded from the study 
after pre-evaluation angiography. Thirteen (23.6%) of the 
remaining 52 patients had hepatocellular carcinoma and 
39 (76.4%) had metastatic liver cancer. Fifty-two patients 
underwent Y-90  radioembolization  treatment.  Each  pa-
tient’s response to the administered treatment was evalu-
ated using the Response Evaluation Criteria in Solid Tu-
mors (RECIST) and the overall probability of survival was 
displayed graphically by the Kaplan-Meier method.
Results: After Y-90 therapy, 47 patients were follow-up. 
While 57% of the patients responded to treatment as clini-
cal benefit, the disease progressed in 43%. The median 
hepatic progression-free survival time of the patients was 
3.4  months  (95%  confidence  interval  (ci):1.4-5.3)  and 
the overall survival time was 11.3 months (95%, CI:8.7-
14.03). 
Conclusion: This study emphasizes that Y-90 resin mi-
crosphere radioembolization treatment is effective in pa-
tients with unresectable liver cancer.
Key words: Yttrium-90, radioembolization, angiography, 
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INTRODUCTION
Unresectable  liver  cancer  is  a  disease  with  poor 
prognosis that causes a large number of deaths each 
year. Without treatment, survival time is less than 
6 months, while the average survival time is 1.5 
months [1,2,3]. Chemotherapy, transarterial chemo-
embolization, regional radiotherapy, radiofrequen-
cy ablation, radioembolization and transplantation 
are treatment options for this disease. 
Radiotherapy is an alternative choice of treat-
ment for patients that cannot undergo surgery and 
for those that do not benefit from chemotherapy. 
While regional irradiation can be performed with 
external radiotherapy, malign tumors cannot be se-
lectively targeted. Normal hepatocytes have a much 
lower tolerance for the effects of radiation than do 
tumoral tissue. Previous reports indicate that when 
a dose of radiation higher than 43 mGy is adminis-
tered, liver function deteriorates in 50% of patients 
[4]. Higher doses of radiation can be more safely 
administered with conformal or stereotactic radia-
tion therapy. However, the multifocality of metasta-
ses and primary foci and their irregular shapes make 
it difficult to obtain positive results from these types 
of treatments [5]. 
Clinical studies for radioembolization therapy 
began in the 1960s and have received growing at-
tention in the last several years [6,7]. The primary 
purpose of radioembolization therapy is to provide 
an alternative treatment option that will reduce the 
grade of the tumor and extend survival time. While 
liver tumors receive 90% of their supply from the 
hepatic  artery,  the  healthy  parenchyma  receive 
80%  of  their  supply  from  the  portal  vein  [8,9]. 
This  discrimination  in  vascular  perfusion  allows 
for tumor-selective treatment while protecting he-
patic function. During radioembolization therapy, 
microspheres  loaded  with  yttrium-90  (y-90)  are 
selectively infused into the effected hepatic region 
by transarterial catheterization. Microspheres that 
reach the tumor microcirculation use beta emission 
as internal radiation to destroy the tumor. So the 
treatment is named as selective internal radiation 
therapy (SIRT). The half-life of Y-90 is 64.2 hours 
(2.67 days), and it breaks down to zirconium-90. It 
spreads high energy beta particles (max. 2.27 MeV, 
average  0.9  MeV)  that  have  average  tissue  pen-
etration of 2.5 mm and a maximum penetration of 
11mm. Y-90 is produced in nuclear reactors by the 
neutron bombardment of Yttrium-89 [6]. Later, it 
is bound to resin or glass microspheres so that is 
can be used for treatment. Currently, there are two 
microsphere devices available for commercial use, 
including resin microspheres (SIR-Spheres, Sirtex 
Medical, Sydney, Australia) and glass microspheres 
(Therasphere,  MDS  Nordion,  Ottawa,  Ontario, 
Canada). 
Publications demonstrating the effectiveness of 
SIRT are limited in patients with liver metastases 
from gastrointestinal system cancers. 
The results of yttrium-90 (Y-90) resin micro-
sphere radioembolization therapy on patients with 
unresectable liver cancer who do not benefit from 
chemotherapy are presented here in. The results of 
this study are also compared with previously pub-
lished data. 
METHODS
Patients  who  underwent  radioembolization  thera-
py (as determined by the oncology council of our 
hospital) between 2010 and 2012 were included in 
the study. After approval from the ethics commit-
tee, patient data was analyzed retrospectively with 
a radiology/patient information program provided 
by our hospital (MEDI-RIS 11.6 1197/2012 AND 
MEDİ-HASTA  14.22  1997/2010  Hospital  Data 
Processing Center). All of these patients had unre-
sectable primary or metastatic liver cancer originat-
ing from the gastrointestinal tract. Treatment with 
resin microspheres (SIR-Sphere) was administered 
to 52 of the 55 patients who were included in the 
study. Each patient’s response to the treatment was 
evaluated by RECIST (Response Evaluation Crite-
ria in Solid Tumors, second version, 2012) and sur-
vival was determined by the Kaplan-Meier method 
[10]. The average age of the patients was 60 years 
(Range 43-78 years), and 16 were female (31%) 
while 36 were male (69%). Thirteen of the patients 
(23.6%) had hepatocellular carcinoma, 26 (47.3%) 
had  colorectal  cancer,  9  (16.4%)  had  gallbladder 
and bile duct cancer, 2 (3.6%) had pancreatic can-
cer, and 5 (9.1%) had gastric cancer. The average 
time between the diagnosis and the administration 
of therapy was 15.3 months. 43 of the patients were 
administered 690 cycles of chemotherapy prior to 
the treatment without any benefit. Twelve (21.8%) 
patients did not receive chemotherapy prior to the 
procedure, 17 (30.9%) patients received level 1 che-Ö. Özgür et al. Yttrium-90 radioembolization for unresectable liver cancer 12
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motherapy, and 26 (47.3%) patients received level 2 
chemotherapy or higher. Eighteen patients (32.7%) 
had unilober hepatic involvement while 37 (67.3%) 
had  bilober  hepatic  involvement.  Six  patients 
(10.9%) had a solitary hepatic metastasis, 14 pa-
tients had 2-4 (25.5%) metastases, and 35 (63.6%) 
had more than 5 metastases. The average target tu-
mor diameter in the liver was 59.8mm (20-140mm) 
and the average Standardized Uptake Value (SUV) 
in 18-fluoro-deoxyglucose (18-FDG) PET-CT was 
11.7 (0-41) (Table-1).
Table 1. Characteristics of patients GIS: gastrointestinal 
system ALT: alanine aminotransferase
Patient
Characteristic n %
Sex
Male
Female
36
16
69.2
30.8
Age
Median
Range
60
43 - 78
Type of primary cancer
Colorectal
Hepatocellular
Gallbladder and bile ducts
Pancreatic
Upper GIS
26
13
9
2
5
47.3
23.6
16.4
3.6
9.1
Prior lines of treatment
0
1
≥2
12
17
26
21.8
30.9
47.3
Liver metastases
Unilober
Bilober
18
37
32.7
67.3
No of liver metastases measured
1 lesion
2-4 lesions
≥5 lesions
6
14
35
10.9
25.5
63.6
Target lesions diameters, mm
Median
Range
59.8
20 – 140
Baseline ALT, u/l
Median
Range
28.4
8 - 141
When the patients were selected to receive the 
treatment,  hemogram,  liver  function  tests  (ALT 
(alanine  aminotransferase), AST(aspartate  amino-
transferase),  bilirubin,  renal  function  tests  (BUN 
(blood urea nitrogen), creatinine) and bleeding dis-
order tests were performed. ALT and AST values 5 
times higher than normal and bilirubin levels above 
2mg/dl were considered to be contraindications for 
receiving therapy [11,12]. Patients were evaluated 
for hepatic tumor load and hepatic and visceral vas-
cular mapping by dynamic computed tomography 
(Aquilion 64, Toshiba). The treatment was admin-
istered to patients that had a tumor load 70% below 
the hepatic volume [11]. Positron emission tomog-
raphy - computed tomography (PET-CT) (Biograph 
16, TrueD, Siemens) imaging in the nuclear medi-
cine department of our hospital and tumor-marker 
lab tests were performed on all of patients before 
they received treatment. Patients with appropriate 
laboratory and tumor load evaluations were direct-
ed to the interventional radiology angiography unit 
(Infinix DFP-8000A,Toshiba) of our hospital.
The  interventional  part  of  the  treatment  was 
conducted in our angiography unit in two stages. In 
the first stage, hepatic and mesenteric arterial circu-
lation was evaluated by digital subtraction angiog-
raphy (DSA).
Primary  angiographic  evaluation  and  hepatic 
arterial system isolation were also performed in the 
first stage.
The routine angiography protocol for 
radioembolization therapy and the objectives 
for each step are as follows: 
1  - Abdominal  aortography: The  anatomy  of  the 
abdominal aorta and celiac and superior mesenteric 
artery arising levels are determined and variations 
are evaluated. 
2 - Superior mesenteric arteriography: The objec-
tives are to visualize the hepatic vascular structures 
originating  from  the  superior  mesenteric  artery 
(SMA) and to evaluate the portal vein. 
3 - Celiac arteriography: The hepatic artery is ana-
tomically mapped and any variations are noted. The 
gastroduodenal artery (GDA), right-left gastric ar-
teries, and accessary branches are evaluated. 
4  -  Selective  right  hepatic  angiography:  Hepatic 
segments 1,5,6,7 and 8, the middle hepatic artery 
(segment 4), and the cystic artery are evaluated. 
5 – Selective left hepatic angiography: Hepatic seg-
ments 2,3 and 4, the right hepatic artery, the falci-
form artery (if present), the phrenic artery, and ac-
cessary gastric arteries are evaluated. Ö. Özgür et al. Yttrium-90 radioembolization for unresectable liver cancer 13
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6 - Selective gastroduodenal arteriography: Acces-
sary hepatic arteries that originate from the GDA or 
parasitic arteries supplying the tumor are evaluated. 
The hepatic arterial system (evaluated by DSA) 
was classified according to the Hiatt classification 
in our study. The region in the liver that was tar-
geted for treatment was classified and evaluated at 
the same time. Next, the branches in the vascular 
plexus nourishing the treatment area of the liver that 
supply the GDA and other determined extrahepatic 
structures  were  embolized  (Figure  1).  Then,  the 
procedure was terminated after Tc-99m macroag-
gregated albumin (MAA) was administered through 
the artery selected for treatment. Later, the patient 
was evaluated with a gamma camera (Symbia S, 
Siemens) in the nuclear medicine unit and the hepa-
topulmonary shunt rate, the previously administered 
MAA, and extrahepatic escape were evaluated.
Patients with a hepatopulmonary shunt rate be-
low 20% who did not have extrahepatic escape were 
included in the treatment protocol. The dose of y-90 
to be administered was determined according to the 
hepatic tumor load (calculated in CT), body surface 
area, and shunt rate after MAA administration.
Figure 1. Standard GDA embolization a. Selective celiac 
arteriography, b. Selective gastroduodenal arteriography, 
c. Embolized GDA, d. Selective right hepatic arteriogra-
phy after GDA embolization
Figure 2. a, b. Coronal (a) and axial (b) 18-FDG PET-CT before the procedure,
    c, d. Coronal (c) and axial (b) Y-90 PET-CT after the procedureÖ. Özgür et al. Yttrium-90 radioembolization for unresectable liver cancer 14
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In the second stage, microspheres loaded with 
y-90  in  the  calculated  dose  were  administered 
through selective catheterization in the hepatic ar-
tery following the administration of medication for 
pain control and inflammation. After the procedure, 
localization of the applied radioactivity was verified 
with a gamma camera. The patient was observed 
in the clinic for 24 hours where bleeding was con-
trolled and hepatic and renal functions of the patient 
were monitored. 
After the control PET-CT study, patients were 
checked weekly for laboratory tests, their general 
state, any gastrointestinal complications and liver 
function. Response to treatment was evaluated af-
ter 6 weeks by 18-FDG PET-CT and tumor-marker 
tests (Figure 2).
RESULTS
Fifty five patients were included in the study. Pre-
angiography was performed on all 55 patients and 
their hepatic arterial anatomy was classified accord-
ing  to  the  Hiatt  classification.  Forty-one  patients 
had normal anatomy (type-1), the left hepatic artery 
originated from the left gastric artery in 3 patients 
(type 2), and the right hepatic artery branched from 
the superior mesenteric artery in 11 patients (type 
3). The GDA of all of the type 1 and type 2 patients 
was coil embolized. The GDA was embolized in 5 
of the type 3 patients because we planned to treat 
both lobes of their livers, while we did not embolize 
the GDA of the remaining 6 patients because treat-
ment was only planned for one lobe. The accessory 
right gastric artery originating from left hepatic ar-
tery in 3 of the type-1 patients was embolized, and 
the supraduodenal artery branching from the arte-
ria hepatica propria in 2 of the type-1 patients was 
embolized.  Fifty-one  extrahepatic  branches  were 
embolized  in  the  patient  group  for  arterial  isola-
tion (46 GDA, 3 accessory right gastric artery, and 
2 supraduodenal artery). One patient was excluded 
from the study due to the critical narrowing of the 
celiac artery, and two patients were excluded due to 
high hepatopulmonary shunt (20% and above) after 
MAA administration. The remaining 52 patients re-
ceived the treatment. The arteria hepatica propria in 
17 patients, the right hepatic artery in 21 patients, 
the left hepatic artery in 2 patients, and the right and 
left hepatic arteries in 12 patients were catheter-
ized separately, and radioembolization therapy was 
administered by y-90 infusion. The patients were 
infused with an average of 1.6±0.1 GBq (1.4-1.9) 
from microspheres loaded with Y-90.
Forty-seven of the patients treated with radio-
embolization were seen regularly for follow-up and 
their results were documented. We were unable to 
follow-up with five of the patients.
The patients were examined for the side-effects 
of the treatment with a weekly clinical examination 
and laboratory studies. Fifteen patients (31.9%) had 
symptoms such as weakness, epigastric pain, vom-
iting and nausea. A gastric ulcer was discovered in 
the endoscopy results of 3 patients (6.4%), while the 
epigastric pain, gastritis, and the symptoms of the 
other patients regressed. 
Tumor response to the treatment was evaluated 
after 6 weeks by PET-CT and tumor-marker analy-
sis  according  to  Response  Evaluation  Criteria  In 
Solid Tumors (RECIST).
We  found  stabile  disease  (SD)  in  5  patients 
(9.1%), a partial response in 19 patients (34.5%), 
a complete response in 3 patients (5.5%), and pro-
gression development in 20 patients (36.4%). Eight 
of the patients could not be evaluated (14.5%) (Ta-
ble 2).
Table 2. Response to treatment according to RECIST
Response No %
Valid  CR 3 5.5
PR 19 34.5
SD 5 9.1
PD 20 36.4
Non-evaluable 8 14.5
Total 55 100.0
PD: progressive disease, SD: stabile disease, PR: Partial 
Response, CR; Complete response
The median hepatic progression free survival 
was 3.4 months (95% ci:1.4-5.3) and overall sur-
vival was calculated to be 11.3 (95% ci:8.7-14.03) 
months. The median survival time for patients with 
colorectal  cancer  and  liver  metastasis  after  Y-90 
radioembolization was 10.6 months (95% ci: 3.8-
17.4). Hepatic progression free survival probabil-
ity as determined by the Kaplan-Meier method is 
shown in Figure 3. Overall survival probability as Ö. Özgür et al. Yttrium-90 radioembolization for unresectable liver cancer 15
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determined by the Kaplan-Meier method is shown 
in Figure 4. Hepatic progression-free survival for 
the colorectal cancer patients was 3.2 months and 
was 3.6 months for the upper gastrointestinal tract, 
bile duct, hepatocellular and pancreatic cancer pa-
tients. There was no statistically significant differ-
ence in progression-free survival between the two 
groups (p= 0.20).
Figure 3. Hepatic progression free survival in 52 patients 
treated by Y-90 resin microsphere radioembolization. The 
solid line displays the Kaplan-Meier estimator with marks 
representing censored events
Figure 4. Overall survival in 52 patients treated by Y-90 
resin microsphere radioembolization. The solid line dis-
plays the Kaplan-Meier estimator with marks representing 
censored events
DISCUSSION
In most cases, tumors in patients with primary and 
secondary liver cancer cannot be removed surgical-
ly and chemotherapy is often ineffective. Therefore, 
this patient group suffers a vast amount of pain and 
deaths each year. Alternative methods of treatment 
are being studied in order to extend healthy survival 
in these patients. Alternative choices of treatment 
include  transarterial  chemoembolization,  regional 
radiotherapy, RF ablation, and radioembolization.
The  effectiveness  of  Y-90  radioembolization 
for the treatment of unresectable liver cancer has 
been emphasized in several studies [13,14,15]. This 
treatment is clinically well tolerated. In our study, 
3 patients (6.4%) developed the major complica-
tion of a gastric ulcer. Other general clinical com-
plaints include weakness, epigastric pain, vomiting 
and nausea. Various experimental clinical studies 
have been conducted to evaluate the combination 
of different chemotherapy protocols with Y-90 ra-
dioembolization.  It  has  been  shown  that  patients 
receiving this combination have extended survival 
rates when compared to patients receiving only che-
motherapy or chemotherapy together with biologi-
cal  treatments.  Therefore,  radioembolization  can 
be accepted as a treatment method used in the first 
level together with chemotherapy [16,17]. Accord-
ing to a meta-analysis by Vente et al. that covers 19 
studies and 792 patients, the response to therapy in 
salvage treatment (any response involving CR,PR 
or SD) in combination with 5-fluorouracil/ leucovo-
rin (5-FU/LV) is 79%, in combination with 5-FU/
LV/oxaliplatin or 5-FU/LV/irinotecan is 91%, and 
is also 91% when used as a first-line therapy [18]. 
While reported response rates for patients treated 
only with y-90 radioembolization vary between 44-
61% for CR/PR, 34-47% for SD, and 4-22% for PD 
[19,20,21], the rates were 46.6%, 10.6% and 42.6%, 
respectively,  in  our  study.  The  clinical  benefit 
(CR+SD+PR) response rate of Y-90 radioemboliza-
tion of the patients that we were able to evaluate in 
our clinic was 57.4%. We believe that the difference 
between these rates is due to the heterogeneity of 
the patient groups. The results of this study empha-
size that Y-90 resin microsphere radioembolization 
treatment is effective on lesions in the liver.
In our study, the median survival time for pa-
tients  with  colorectal  cancer  and  liver  metastasis 
after Y-90 radioembolization was 10.6 months and Ö. Özgür et al. Yttrium-90 radioembolization for unresectable liver cancer 16
Dicle Tıp Derg / Dicle Med J    www.diclemedj.org   Cilt / Vol 41, No 1, 10-16
the toxicities determined were <10%. The overall 
survival time in our patients was 11.3 months and 
the requiring hospitalisation toxicity was 6%. 
This  study  emphasizes  the  effectiveness  of 
Y-90 radioembolization for the treatment of patients 
with unresectable liver cancer or liver metastases 
from gastrointestinal system cancers. Radioembo-
lization with Y-90 is a treatment method that should 
be taken into consideration for appropriate patients 
with gastrointestinal system cancers. 
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